OncoImmunity was acquired by NEC.

Norway M&A 29 July 2019
Share on FacebookShare on Twitter

OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer.

The financial details of the transaction remained undisclosed. OncoImmunity AS will become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity AS, founded in 2014 and led by CEO Richard Stratford, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.

OncoImmunity was funded by external investors including RadfForsk (Norwegian Radium Hospital Research Foundation) and StartupLab.